PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As part of a rapid-fire expansion across Asia, the U.S.-headquartered PPD has outlined plans to purchase and merge with the Beijing-based contract research organization BioDuro
You may also be interested in...
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 1 Of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.